|

Maralixibat Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Formerly LUM001, SHP625, Livmarli Oral Solution, TAK-625

Pipeline

Phase 3: 1

Top Sponsors

  • Takeda1
  • Mirum Pharmaceuticals, Inc.1

Indications

  • Liver Disease2
  • Alagille Syndrome (ALGS)1
  • Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)1
  • Progressive Familial Intrahepatic Cholestasis (PFIC)1
  • Heart Disease1

Other1 trial

A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

Los Angeles, California1 trial

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Children's Hospital Los Angeles (CHLA)

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.